# OnCo record fgfr3-alteration (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/fgfr3-alteration/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "fgfr3-alteration" ;
  schema:name "FGFR3 alteration (mutation or fusion)"@en ;
  schema:alternateName "FGFR3 mutation"@en, "FGFR3 fusion"@en, "FGFR3-TACC3"@en, "FGFR3::TACC3"@en, "FGFR3 S249C"@en, "FGFR3 R248C"@en, "FGFR3 Y373C"@en, "susceptible FGFR3 genetic alterations"@en, "FGFR alteration bladder"@en ;
  schema:description "FGFR3 point mutations and TACC3 fusions drive about 15 to 20 percent of advanced bladder cancers. Erdafitinib is approved for tumours with these 'susceptible' alterations after one prior treatment."@en ;
  schema:url <https://onco.cc/biomarkers/fgfr3-alteration/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee> ;
  onco:tag "biomarker", "fgfr" ;
  onco:related <https://onco.cc/biomarkers/fgfr2-fusion-rearrangement/> ;
  onco:cancers <https://onco.cc/cancers/urothelial/> ;
  onco:drugs <https://onco.cc/drugs/erdafitinib/>, <https://onco.cc/drugs/therascreen-cdx/> ;
  onco:terms <https://onco.cc/terms/fgfr3/>, <https://onco.cc/terms/gene-fusion/> .